Product information and disease descriptionProduct descriptionProduct information
Special populations
5 evidence topics · 4 sources
Age range studied: ARCHER II
Age range studied: ARCHER
Age range studied: phase I glaucoma studies
“In the phase Ia study, eligible patients were aged ≥ 18 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase Ib study, eligible patients were aged ≥ 18 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age overall was 70 years in phase Ia and 68 years in phase Ib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age of enrolled participants: ARCHER and ARCHER II
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
Pregnancy, breastfeeding, and contraception: ARCHER eligibility criterion
Pediatric use, renal impairment, and hepatic impairment
No evidence found.